RA190

01/01/2021 - "RA183 and RA375 are more potent analogs of the prototypic inhibitor of RPN13 (iRPN13) called RA190, and they show promise for the treatment of ovarian cancer. "
08/07/2017 - "Ovarian cancer cell lines are sensitive to RA190 regardless of whether the ADRM1 gene is amplified."
08/07/2017 - "No correlation was found between ADRM1 amplification and sensitivity of ovarian cancer cell lines to RA190, but all were susceptible. "
08/07/2017 - "Amplification of ADRM1 and sensitivity to RA190 were determined in ovarian cancer cell lines. "
08/07/2017 - "Here, we sought to determine if RPN13 is available as a target in precursors of ovarian/fallopian tube cancer as well as all advanced cases, and the impact of increased ADRM1 gene copy number on sensitivity of ovarian cancer to RA190. "

01/01/2016 - "MM xenograft model studies show that RA190 is well tolerated, inhibits tumor growth and prolongs survival. "
11/19/2020 - "Cys88 of Rpn13 has been proposed to be the principal target of RA190, an electrophilic small molecule with interesting anti-cancer activities. "
05/06/2020 - "Treatment of mice bearing an orthotopic HCC model with RA190 significantly reduced tumor growth. "
01/01/2018 - "The in vivo anti-tumor effect of RA190 on ICC was validated in subcutaneous xenograft and patient-derived xenograft (PDX) models. "
10/18/2016 - "Finally, we show that RA190 treatment of mice bearing syngeneic ovarian tumor elicits potent CD8+ T cell antitumor immune responses and improves tumor control and survival. "

01/01/2018 - "RA190, a Proteasome Subunit ADRM1 Inhibitor, Suppresses Intrahepatic Cholangiocarcinoma by Inducing NF-KB-Mediated Cell Apoptosis."

12/09/2013 - "Multiple myeloma (MM) lines, even those resistant to bortezomib, were sensitive to RA190 via endoplasmic reticulum stress-related apoptosis. "

11/19/2020 - "Finally, increasing or reducing the level of Rpn13 in HeLa and melanoma cells had no effect on the sensitivity of HeLa or melanoma cells to RA190. "